A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C)

European Journal of Clinical Pharmacology

Volumn 67, Issue 11, 2011, Pages 1131-1137

  Brasch Andersen, Charlotte ^a   Møller, Malik U ^a   Christiansen, Lene ^a,b   Thinggaard, Mikael ^b   Otto, Marit ^a,c   Brøsen, Kim ^a,b   Sindrup, Søren H ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Neuropathic pain; Pharmacogenetics; SSRI treatment; Treatment response

Indexed keywords

CYSTEINE; ESCITALOPRAM; GLYCOPROTEIN P; PLACEBO; SERINE;

ABCB1 GENE; ANALGESIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYP2C19 GENE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; MALE; NEUROPATHIC PAIN; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR GENE; SEROTONIN RECEPTOR 2A GENE; SEROTONIN RECEPTOR 2C GENE; SEROTONIN TRANSPORTER GENE; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM;

CITALOPRAM; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; NEURALGIA; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 80054726619     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1056-x     Document Type: Article

References (25)

1. NB Finnerup SH Sindrup TS Jensen 2010 The evidence for pharmacological treatment of neuropathic pain Pain 150 573 581 20705215 10.1016/j.pain.2010.06. 019
2. SH Sindrup M Otto NB Finnerup TS Jensen 2005 Antidepressants in the treatment of neuropathic pain Basic Clin Pharmacol Toxicol 96 399 409 15910402 10.1111/j.1742-7843.2005.pto-96696601.x 1:CAS:528:DC%2BD2MXlt1ynur4%3D (Pubitemid 40835693)
3. SH Sindrup LF Gram K Brosen O Eshoj EF Mogensen 1990 The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms Pain 42 135 144 2147235 10.1016/0304-3959(90)91157- E 1:STN:280:DyaK3M%2Fmt1Whtg%3D%3D (Pubitemid 20258898)
4. SH Sindrup U Bjerre A Dejgaard K Brosen T Aaes-Jorgensen LF Gram 1992 The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy Clin Pharmacol Ther 52 547 552 1424428 10.1038/clpt.1992.183 1:STN:280:DyaK3s%2FkslKnug%3D%3D
5. MB Max SA Lynch J Muir SE Shoaf B Smoller R Dubner 1992 Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy N Engl J Med 326 1250 1256 1560801 10.1056/NEJM199205073261904 1:STN:280: DyaK383itVWgsA%3D%3D
6. M Otto FW Bach TS Jensen K Brosen SH Sindrup 2008 Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial Pain 139 275 283 18547727 10.1016/j.pain.2008.04.012 1:CAS:528:DC%2BD1cXht1Sit73K
7. R Suzuki LJ Rygh AH Dickenson 2004 Bad news from the brain: descending 5-HT pathways that control spinal pain processing Trends Pharmacol Sci 25 613 617 15530638 10.1016/j.tips.2004.10.002 1:CAS:528:DC%2BD2cXpsVSjtrw%3D (Pubitemid 39458166)
8. JA Lopez-Garcia 2006 Serotonergic modulation of spinal sensory circuits Curr Top Med Chem 6 1987 1996 17017969 10.2174/156802606778522159 1:CAS:528:DC%2BD28XhtFens7fI (Pubitemid 44524472)
9. L Christiansen Q Tan M Iachina L Bathum TA Kruse M McGue, et al. 2007 Candidate gene polymorphisms in the serotonergic pathway: influence on depression symptomatology in an elderly population Biol Psychiatry 61 223 230 16806099 10.1016/j.biopsych.2006.03.046 1:CAS:528:DC%2BD2sXmtVGntw%3D%3D (Pubitemid 46072781)
10. S Rodriguez TR Gaunt IN Day 2009 Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies Am J Epidemiol 169 505 514 19126586 10.1093/aje/kwn359
11. GM Tan E Wu YY Lam BP Yan 2010 Role of warfarin pharmacogenetic testing in clinical practice Pharmacogenomics 11 439 448 20402581 10.2217/pgs.10.8 1:CAS:528:DC%2BC3cXlsFeksbc%3D
12. AR Hughes CH Brothers M Mosteller WR Spreen DK Burns 2009 Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example Pharmacogenomics 10 225 233 19207023 10.2217/14622416.10.2.225 1:CAS:528:DC%2BD1MXhslSgurk%3D
13. JN Hirschhorn G Lettre 2009 Progress in genome-wide association studies of human height Horm Res 71 Suppl 2 5 13 19407491 10.1159/000192430 1:CAS:528:DC%2BD1MXltFOku78%3D
14. A Drago RD De A Serretti 2009 Pharmacogenetics of antidepressant response: an update Hum Genomics 3 257 274 19403460 1:CAS:528: DC%2BC3cXpt1yrs7o%3D
15. M Kato R Zanardi D Rossini RD De G Okugawa T Kinoshita, et al. 2009 5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients Psychiatry Res 167 97 105 19361869 10.1016/j.psychres.2007.12.012 1:CAS:528:DC%2BD1MXkslOitbo%3D
16. M Okada JK Northup N Ozaki JT Russell M Linnoila D Goldman 2004 Modification of human 5-HT(2C) receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution Mol Psychiatry 9 55 64 14699441 10.1038/sj.mp.4001357 1:CAS:528:DC%2BD3sXhtVWhsbfK (Pubitemid 38175082)
17. HM Fentress E Grinde JE Mazurkiewicz JR Backstrom K Herrick-Davis E Sanders-Bush 2005 Pharmacological properties of the Cys23Ser single nucleotide polymorphism in human 5-HT2C receptor isoforms Pharmacogenomics J 5 244 254 15912142 10.1038/sj.tpj.6500315 1:CAS:528:DC%2BD2MXmsVyjs70%3D (Pubitemid 41131716)
18. KP Lesch D Bengel A Heils SZ Sabol BD Greenberg S Petri, et al. 1996 Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region Science 274 1527 1531 8929413 10.1126/science.274.5292.1527 1:CAS:528:DyaK28Xnt1ansL8%3D (Pubitemid 26403928)
19. P Eichhammer B Langguth R Wiegand A Kharraz U Frick G Hajak 2003 Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI) Psychopharmacol (Berl) 166 294 297 1:CAS:528:DC%2BD3sXitFGmtLg%3D (Pubitemid 36384777)
20. S Potvin A Larouche E Normand JB de Souza I Gaumond S Marchand, et al. 2010 No relationship between the ins del polymorphism of the serotonin transporter promoter and pain perception in fibromyalgia patients and healthy controls Eur J Pain 14 742 746 20080425 10.1016/j.ejpain.2009.12.004 1:CAS:528:DC%2BC3cXovFeltbg%3D
21. RB Kim BF Leake EF Choo GK Dresser SV Kubba UI Schwarz, et al. 2001 Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 189 199 11503014 10.1067/mcp.2001. 117412 1:CAS:528:DC%2BD3MXmslygs7o%3D (Pubitemid 32777772)
22. C Marzolini E Paus T Buclin RB Kim 2004 Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance Clin Pharmacol Ther 75 13 33 14749689 10.1016/j.clpt.2003.09.012 1:CAS:528:DC%2BD2cXntVKiuw%3D%3D (Pubitemid 38130115)
23. M Kato T Fukuda A Serretti M Wakeno G Okugawa Y Ikenaga, et al. 2008 ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder Prog Neuropsychopharmacol Biol Psychiatry 32 398 404 17913323 10.1016/j.pnpbp.2007.09.003 1:CAS:528:DC%2BD1cXhsVKitLk%3D (Pubitemid 351178955)
24. L Noehr-Jensen ST Zwisler F Larsen SH Sindrup P Damkier F Nielsen, et al. 2009 Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker Eur J Clin Pharmacol 65 887 894 19404631 10.1007/s00228-009-0657-0 1:CAS:528:DC%2BD1MXhtVehu77P
25. SC Sim C Risinger ML Dahl E Aklillu M Christensen L Bertilsson, et al. 2006 A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 103 113 16413245 10.1016/j.clpt.2005.10.002 1:CAS:528:DC%2BD28XksVGltw%3D%3D (Pubitemid 43069582)